| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. | Chief Development Officer | Common Stock | 176,995 | $6,663,862 | $37.65 | 01 Mar 2022 | Direct |
| Crinetics Pharmaceuticals, Inc. | Chief Development Officer | Common Stock (right to buy) | 65,400 | $1,442,724 | $22.06 | 28 Feb 2022 | Direct |
| Crinetics Pharmaceuticals, Inc. | Chief Development Officer | Stock Option (right to buy) | 0 | 28 Oct 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | 28 Feb 2022 | 3 | +$178,920 | 4 | Chief Development Officer | 02 Mar 2022, 20:00 |
| CRNX | Crinetics Pharmaceuticals, Inc. | 07 Feb 2022 | 1 | -$239,085 | 4 | Chief Development Officer | 09 Feb 2022, 16:00 |
| CRNX | Crinetics Pharmaceuticals, Inc. | 31 Dec 2021 | 1 | +$8,651 | 5 | Chief Development Officer | 04 Feb 2022, 15:26 |
| CRNX | Crinetics Pharmaceuticals, Inc. | 28 Oct 2021 | 2 | +$77,660 | 4 | Chief Development Officer | 01 Nov 2021, 19:11 |